DeutschNewstral
Article
jdsupra.com on 2023-08-23 18:54
Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patent
Related news
- Mylan Files IPR on Regeneron Aflibercept Patentjdsupra.com
- Celltrion Files IPR Petition on Aflibercept Patentjdsupra.com
- EYLEA® (aflibercept) IPR and BPCIA Litigation Updatesjdsupra.com
- EYLEA® (aflibercept) and Soliris® (eculizumab) IPR Updatesjdsupra.com
- Samsung Files IPR Petition on Regeneron’s Aflibercept Patentjdsupra.com
- Post-Trial Updates on Regeneron v. Mylan (Aflibercept) BPCIA Litigationjdsupra.com
- Stelara® Biosimilar Updates: IPR Petition Challenging U.S. Patent No. 10,961,307 Filed and SB17 Settlement and Launch Date Announcedjdsupra.com
- PTAB Institutes Celltrion and Biocon IPRs on Regeneron Aflibercept Dosing Patentjdsupra.com
- Regeneron Moves to Terminate Celltrion IPR on Aflibercept Patent After Regeneron Files Statutory Disclaimerjdsupra.com
- Aflibercept IPR Updates - July 2023jdsupra.com
- Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Ordersjdsupra.com
- Regeneron v. Mylan - Update on Aflibercept BPCIA Litigationjdsupra.com
- Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Casejdsupra.com
- Celltrion and Samsung File IPR Petitions on Aflibercept Patentsjdsupra.com
- Mylan Files New IPR Petitions on Aflibercept Patentsjdsupra.com
- Expedited Trial Ordered in Regeneron Aflibercept BPCIA Case Against Mylanjdsupra.com
IPR process reshapes patent litigationbizjournals.com- Regeneron’s Disputes with Celltrion, Samsung Bioepis, and Formcycon on Service and Personal Jurisdiction in Aflibercept BPCIA Litigationjdsupra.com
- Update: Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Case Now Completejdsupra.com
- Federal Circuit Dismisses Appeals in Regeneron v. Mylan (Aflibercept) BPCIA Litigationjdsupra.com